<DOC>
	<DOCNO>NCT00368862</DOCNO>
	<brief_summary>The aim present study examine influence memantine , noncompetitive NMDA receptor blocker , depression co-morbid long term alcohol heavy use compare SSRI-inhibitor , escitalopram . Second goal compare influence cognitive task third goal follow alcohol-use two medicine .</brief_summary>
	<brief_title>Efficacy Study Memantine Hydrochloride Escitalopram Treatment Co-Morbid Depression Alcoholism .</brief_title>
	<detailed_description>Context Depression common clinical problem among alcoholic treatment standard controversy . Glutamate NMDA-receptors may mediate effect long term alcohol relate depression thus NMDA-receptor modulator memantine could effect . Objectives The preliminary aim study identify possible new treatment depression alcoholic compare efficacy escitalopram memantine co-morbid depression alcoholism . Design set Double-blind , randomize , naturalistic study , 26-week trial alcohol dependent outpatient . Participants Eighty alcohol dependent depressive adult Intervention Subjects randomize 1:1 receive memantine escitalopram 20 mg per day . During study patient receive routine psychosocial treatment A-Clinic . No concomitant intervention alcohol consumption impose treatment goal . The patient meet weekly first month , 3 6 month .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>1 . The subject/patient able read understand subject/patient information sheet . 2 . Prior screening procedure , subject/patient must sign informed consent form . No studyrelated procedure may perform subject/patient sign form . 3 . Age 2570 year 4 . Heavy alcohol consumption ( male 5 doses/ day , female 4 doses/day ) least 10 year 5 . Alcohol dependence ( DSMIV ) assess SCIDI interview . 6 . Major depression ( DSMIV ) assess SCIDI interview . At least 4 week past previous inpatient treatment AWS ( alcohol withdrawal syndrome ) . 1 . Other drug dependence ( screened urine test ) 2 . Other serious mental illness ( DSMIV ) 3 . Hazard suicide 4 . Pregnancy 5 . Serious kidney , hart thyroid problem 6 . The subject/patient , opinion investigator , unlikely comply clinical study protocol unsuitable reason . 7 . Liver cirrhosis liver enzymes ASAT tai ALAT &gt; 200 . 8 . The person meet criterion state Finnish Law Clinical Studies , paragraph 710ยง ( child , pregnant , imamates mentally handicap ) .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Depression</keyword>
	<keyword>Efficacy study</keyword>
	<keyword>Memantine</keyword>
	<keyword>Escitalopram</keyword>
</DOC>